> ## Documentation Index
> Fetch the complete documentation index at: https://docs.hi-doctor.ai/llms.txt
> Use this file to discover all available pages before exploring further.

# Minoxidil — topical vs oral, evidence and side effects

> Minoxidil comes as an EU-authorised topical treatment and an off-label oral tablet for hair loss. How each works, the trial evidence and side effects.

Minoxidil comes in two very different forms, and the difference matters. The liquid or foam applied to the scalp is a properly authorised medicine for male pattern hair loss in EU countries, sold both on prescription and over the counter. Minoxidil also exists as a tablet, but in the EU those tablets are only licensed as a blood-pressure medicine — taking low-dose minoxidil tablets for hair is off-label, meaning a doctor prescribes it outside its licensed use.

<Info>
  Active ingredient: **minoxidil**. Dosages: **5% topical** solution or foam, or **2.5–5 mg oral** (off-label for hair).
</Info>

## How it works

Applied to the scalp, minoxidil opens ATP-sensitive potassium channels, widens small blood vessels and appears to keep hair follicles in their growing phase for longer — although exactly how it acts on hair is still not fully understood.

<Tabs>
  <Tab title="Topical (authorised)">
    A properly authorised EU medicine for male pattern hair loss, applied twice daily to a dry scalp — 1 mL, not rinsed for at least 4 hours. This is the form the trial evidence below is based on.
  </Tab>

  <Tab title="Oral (off-label)">
    In the EU, minoxidil tablets are only licensed for severe resistant high blood pressure — never alone, always alongside a beta-blocker and a diuretic. Low-dose oral minoxidil for hair loss is prescribed off-label, under medical supervision.
  </Tab>
</Tabs>

## EU authorisation

Minoxidil has been authorised for use in the EU since **1 May 1988** (AEMPS CIMA, Regaxidil 20 mg/ml solución cutánea, Spain registration 57597, indicated for moderate androgenetic alopecia).

## What the studies reported

The core hair-loss trial (Olsen et al., *J Am Acad Dermatol* 2002;47(3):377-385, PMID 12196747) ran for 48 weeks in men aged 18–49 with vertex-pattern loss, so it does not establish results beyond one year or in other patterns of hair loss.

## What has been reported

| Reaction                                                          | Frequency (topical) |
| ----------------------------------------------------------------- | ------------------- |
| Itching, dermatitis, acneiform dermatitis, rash                   | Common              |
| Hypertrichosis (unwanted hair growth), incl. facial hair in women | Common              |
| Headache, dyspnoea                                                | Common              |
| Dizziness, nausea, peripheral oedema                              | Uncommon            |
| Palpitations, tachycardia, chest pain                             | Rare                |
| Low blood pressure, allergic reactions incl. angioedema           | Not known           |
| Temporary increased shedding                                      | Not known           |

Application-site reactions can occasionally be more severe and include peeling, blistering, bleeding or ulceration.

<AccordionGroup>
  <Accordion title="Oral minoxidil vs topical — randomised comparison">
    In a 24-week randomised trial of oral minoxidil 5 mg vs topical minoxidil 5% (n=45 per arm), hypertrichosis occurred in **22/45 (49%)** on the oral drug vs **11/45 (25%)** on topical (P=.02), and headache in **6/45 (14%)** vs **1/45 (2%)** (P=.046). Scalp eczema was more frequent with topical: 7/45 (16%) vs 1/45 (2%). (Penha MA, Miot HA, Kasprzak M, Muller Ramos P. *JAMA Dermatol.* 2024;160(6):600-605, PMID 38598226.)
  </Accordion>

  <Accordion title="Oral minoxidil — large observational series">
    In a retrospective multicentre study of 1,404 patients treated for at least 3 months, the most frequent adverse effect was hypertrichosis (**15.1%**, causing withdrawal in 0.5%). Systemic effects: lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9%, headache 0.4%, periorbital oedema 0.3%, insomnia 0.2% — leading to discontinuation in 1.2% of patients. (Vaño-Gálvan S, Pirmez R, Hermosa-Gelbard A, et al. *J Am Acad Dermatol.* 2021;84(6):1644-1651, PMID 33639244.)
  </Accordion>

  <Accordion title="What oral minoxidil tablets are actually licensed for in the EU">
    EU-authorised minoxidil tablets are indicated only for severe resistant high blood pressure, and their product information states they must never be used alone or as initial therapy — always alongside a beta-blocker and a diuretic. None of that licensed dosing framework applies to the low doses used off-label for hair loss.
  </Accordion>
</AccordionGroup>

## How it pairs with other treatments

Minoxidil is frequently combined with a 5-alpha-reductase inhibitor: minoxidil stimulates the follicle while finasteride or dutasteride blocks the hormonal cause. The doctor decides the form and combination based on history and pattern of loss.

## How Hi-Doctor handles it

**Weeks 1–8** — build the daily routine.

A doctor reviews every hair-growth option and recommends what fits the case history and goals — topical or oral, depending on presentation. The consultation fee is separate from the medicine, which is paid at a pharmacy; see [pricing](/essentials/pricing).

## Sources

* AEMPS CIMA — Regaxidil 20 mg/ml solución cutánea, ficha técnica (Spain, registration 57597, authorised 1 May 1988)
* AEMPS CIMA — Regaine 50 mg/g espuma cutánea, ficha técnica (Spain, registration 76483)
* AEMPS CIMA — Loniten 10 mg comprimidos, ficha técnica (Spain, registration 55636; oral minoxidil, severe hypertension only)
* AEMPS CIMA — Minogal 2,5/5/10 mg comprimidos EFG, ficha técnica (Spain, registration 91045-91047, authorised 2026; oral minoxidil, severe resistant hypertension only)
* Olsen et al., *J Am Acad Dermatol* 2002;47(3):377-385 (PMID 12196747)
* Penha MA, Miot HA, Kasprzak M, Muller Ramos P. *JAMA Dermatol.* 2024;160(6):600-605 (PMID 38598226)
* Vaño-Gálvan S, Pirmez R, Hermosa-Gelbard A, et al. *J Am Acad Dermatol.* 2021;84(6):1644-1651 (PMID 33639244)
* Rodrigues Dias F, Yong SS, FitzGerald H, Sinclair RD, Bhoyrul B. *Front Pharmacol.* 2026;16:1718208

## Common questions

<AccordionGroup>
  <Accordion title="How long before I see results with minoxidil?">
    First changes are usually seen at months 2–4 of consistent twice-daily use. The core trial ran for 48 weeks and does not establish results beyond one year. Results vary by person and pattern of hair loss.
  </Accordion>

  <Accordion title="Can I use topical minoxidil once a day instead of twice?">
    The EU-authorised regimen is 1 mL applied twice daily to a dry scalp, not rinsed for at least 4 hours. Using it less often may reduce its effect. Discuss any change with your doctor.
  </Accordion>

  <Accordion title="Does minoxidil cause hair shedding at first?">
    Temporary increased shedding is listed in the EU product information at a frequency that is not known. This can happen in the first weeks as the hair cycle adjusts and usually resolves with continued use.
  </Accordion>

  <Accordion title="Is oral minoxidil safe for hair loss?">
    Low-dose oral minoxidil is prescribed off-label under medical supervision. In a large observational study of 1,404 patients, the most frequent side effect was unwanted hair growth (hypertrichosis) in 15.1%, and systemic effects leading to discontinuation occurred in 1.2%. Your doctor monitors for cardiovascular effects.
  </Accordion>

  <Accordion title="Can I combine minoxidil with finasteride?">
    Yes. Minoxidil and finasteride work by different mechanisms — minoxidil stimulates the follicle while finasteride blocks the hormonal cause. The combination is frequently used. A doctor decides the form and combination based on your history.
  </Accordion>

  <Accordion title="Is minoxidil authorised in the EU?">
    Yes for the topical form. Minoxidil has been authorised for use in the EU since 1 May 1988 (AEMPS CIMA, Regaxidil 20 mg/ml solution cutánea, Spain registration 57597, indicated for moderate androgenetic alopecia). The oral tablet is authorised only for severe resistant high blood pressure.
  </Accordion>
</AccordionGroup>

## Related reading

* [Minoxidil medicine page](/library/medicines/minoxidil)
* [Finasteride — how it works and evidence](/library/medicines/finasteride)
* [Minoxidil treatment guide](/library/guides/hair-growth-minoxidil)
* [Androgenetic alopecia](/library/conditions/androgenetic-alopecia)
* [How a consultation works](/essentials/how-it-works)
* [Safety and eligibility](/essentials/safety)

## Start a consultation

<Card title="Hair-growth consultation" icon="stethoscope" href="https://hi-doctor.ai/consultation/hair-growth/1">
  Answer the hair-growth questionnaire and a registered doctor reviews it.
  They decide whether treatment is appropriate, which one, and at what dose —
  and declining is a normal outcome. See [what it costs](/essentials/pricing)
  and [how the review works](/essentials/how-it-works).
</Card>

<Warning>
  This page is reference information, not medical advice and not a prescription. Whether a medicine is appropriate for you is decided by a registered doctor after reviewing your consultation.
</Warning>